Intellia Therapeutics Inc buy Savour
Start price
24.01.21
/
20%
€63.50
Target price
24.01.22
-
Performance (%)
-15.72%
End price
11.03.21
€53.52
Summary
This prediction ended on 11.03.21 with a price of €53.52. The prediction for Intellia Therapeutics Inc disappointed with a performance of -15.72%. Savour has 20% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intellia Therapeutics Inc | -6.050% | -6.050% | 42.510% | -73.770% |
| iShares Core DAX® | -2,80 % | -1,40 % | -0,22 % | 48,43 % |
| iShares Nasdaq 100 | -6,35 % | -0,41 % | 29,00 % | 84,28 % |
| iShares Nikkei 225® | -6,94 % | -0,28 % | 48,21 % | 59,28 % |
| iShares S&P 500 | -3,41 % | 0,40 % | 20,28 % | 62,51 % |
According to Savour what are the pros and cons of Intellia Therapeutics Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by Savour for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Buy Intellia Therapeutics Inc